Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...

NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...

NuCana called the cancellation of the study, which followed a committee recommendation, a ‘disappointing’ and ‘unexpected ...

NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...

NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...

NuCana公司简介。此公司档案包括NuCana(NCNA)公司所处行业，业务概况，地址，联系方式，官网和高管档案资料。 NuCana PLC是一家英国临床阶段生物制药公司。该公司使用ProTide科技为癌症病人开发治疗方法。ProTide旨在克服癌症耐药机制并在癌细胞中产生抗癌代谢物。

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...

Investing.com – 美国股市在星期二涨跌不一，其中石油和天然气、消费服务和金融等上涨的板块带领股指走高；与此同时，电信、卫生保健和生活消费品板块等下跌的使股指走低。

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...

华盛资讯9月16日消息，美股三大期指盘前小幅走高，特朗普媒体科技集团盘前涨5%，消息面上，美国前总统特朗普疑再遭“暗杀未遂”，据报周天特朗普在佛罗里达州的高尔夫球场再次遭遇枪击。不过幸运的是，他没有受伤。

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00.

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.